Pharma's Almanac TV
PA TV
Follow the Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Current Issue
Archive
Reports
2021 Gene Therapy Report
2021 Biologics Report
2021 Sterile Drug Products Report
2021 API Market Report
2020 OSD Market Report
Community
Company A to Z
More+
Staffing
Media Kit
Drug Development
615 Articles Available
1
26
Can't find what you're looking for? Try our
advanced search
.
Oncology
HEALED Consortium Successful in a €10.5M DTIF-Supported Program to Develop Groundbreaking New Therapies for Currently Incurable Cancers
PR-M04-21-031
Immunity
The Link Between COVID-19 and Immunity
PTV-04-21-CL-003
Virtual Reality
Perception is Reality: Integrating Virtual and Augmented Reality Across Pharma
PAO-04-21-NI-02
Blockchain
Using Blockchain to Drive Drug Development and Healthcare Data Management
PAO-04-21-NI-01
Plant-Based
Exploring the Natural Pharmacopeia and Incubating a Biotech Company
PAO-02-21-CL-06
Gene Therapy
Avoiding Costly And Time-Consuming Mistakes In Gene Therapy Process Development
PAO-03-21-CL-08
Stem Cells
Curi Bio Raises $6M Series A Financing Round for iPSC-derived Predictive Platforms
PR-M03-21-004
Preclinical
Increasing the Efficiency of Drug Development with Preclinical Testing Using Human Intestinal Stem Cells
PAO-11-20-CL-01
The Future of Healthcare
How Does Polpharma Biologics Envision the Future of the Pharma/Biopharma Industry?
PAP-Q4-20-RT2-010
Roundtable
Q: Although there is no such thing as a truly “crisis-proof” organization, how are you working to mitigate risks for future crises like the COVID-19 pandemic?
PAP-Q4-20-NI-007
Gene Therapy
Anticipating the Next Decade of Gene Therapy
PAO-11-20-CL-02
Microbiome CDMO
Extensive Experience Is Crucial to Speed to the Clinic and Market for Live Biotherapeutic Products
PAP-Q3-20-CL-004
Lipid Excipients
Successful Drug Development with Synthetic Lipids: Critical Aspects and Strategies
PAP-Q3-20-CL-024
Organ-on-a-Chip
Organ-on-a-Chip Technology Aims to Disrupt Traditional Drug Testing Models
PAP-Q3-20-CL-014
The Future of Healthcare
How Is Polpharma Biologics Evolving its Business Model to Meet the Future of Healthcare?
PAP-Q3-20-RT2-007
Microphysiological Systems
Accelerating Drug Development with Microphysiological Systems (MPS)
PAP-Q3-20-CL-003
Endocannabinoid System
Realizing the Promise of Therapeutics Targeting the Endocannabinoid System
PAP-Q3-20-CL-005
Roundtable
Q: What steps is your company taking to address drug pricing issues?
PAP-Q3-20-NI-008
Drug Development
Alaxia Breaks New Ground With Lead Compound ALX‑009 as Virucidal Agent
PR-M09-20-24
Migraines
REYVOW Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase Study
PR-M09-20-22
Clinical Results
AstraZeneca's Drug Significantly Reduces the Rate of the Composite of Stroke and Death in Patients
PR-M07-20-NI-027
COVID-19 Trial Data
Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19
PR-M07-20-NI-015
Capacity Expansion
Vetter Further Expands its Development Service with New Site in Austria
PR-M07-20-NI-010
Chronokines
Delivering Breakthrough Medicines for Rare Hematologic Diseases and Cancers
PAP-Q2-20-CL-003
1
26
»
